Quick Answer
Kymera Therapeutics, Inc. reported Research And Development Expense of $316.57 million for the year ending 2025.
- Kymera Therapeutics, Inc. showed an increase of +31.8% in Research And Development Expense from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $11.31 million | Q1 2020: $12.12 million | Q2 2020: $13.82 million | Q3 2020: $15.78 million | Q1 2021: $25.96 million | Q2 2021: $35.22 million | Q3 2021: $38.31 million | Q1 2022: $35.94 million | Q2 2022: $41.29 million | Q3 2022: $43.88 million | Q1 2023: $42.23 million | Q2 2023: $45.77 million | Q3 2023: $48.12 million | Q1 2024: $48.82 million | Q2 2024: $59.20 million | Q3 2024: $60.41 million | Q1 2025: $80.26 million | Q2 2025: $78.39 million | Q3 2025: $74.09 million.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Research And Development Expense has grown by 752.0%.
- Historical annual values: Fiscal year 2025: $316.57 million | Fiscal year 2024: $240.25 million | Fiscal year 2023: $189.08 million | Fiscal year 2022: $164.25 million | Fiscal year 2021: $137.02 million | Fiscal year 2020: $62.11 million | Fiscal year 2019: $37.16 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: